Preventing chronicity of migraine by unknown
Introduction
A subgroup of migraine patients have a clinical disorder that
results in headaches that occur on more than 15 days per
month, thus indicating the evolution of episodic migraine
into a chronic form [1]. The International Headache Society
Classification includes the operational diagnostic criteria for
the diagnosis of chronic migraine. This is considered a com-
plication of migraine without aura with 15 or more migraine
days per month. Headache syndromes that occur 15 or more
days per month also include transformed migraine. The term
“transformed” implies a process of change over time with a
history of transformation from episodic to chronic migraine.
Transformed migraine seems to be a clinical form that has a
clinical usefulness in recognition of the migraine subgroup
who have had a chronic evolution from episodic migraine.
Intervention strategies on disease progression are para-
mount goals for the prevention of chronicity of migraine
[2]. Prevention must be carried out against the main mod-
ifiable risk factors that are currently known.
Progression during attacks
Allodynia, pain resulting from application of a non-noxious
stimulus to normal skin, is a recently described symptom of
migraine [3]. In fact clinically detectable allodynia, a mani-
festation of central sensitisation, occurs with high frequency
during migraine attacks. Migraine pain progresses along the
neural pathway with throbbing head pain occurring early in
the attack (sensitisation of first-order neurons), followed by
central sensitisation and cutaneous allodynia within the
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Abstract Chronic migraine and
transformed migraine are conditions
with a progression from episodic to
chronic headache, a disabling stage.
During attack, cutaneous allodynia
frequently occurs: it reflects sensiti-
sation of the central neurons of the
trigeminovascular system. Early
triptan therapy (prior to the devel-
opment of central sensitisation) may
protect from the chronicisation of
migraine. In addition, early recogni-
tion of non-headache changes in
neurologic function between
episodes of headache offers a sensi-
tive indicator of headache transfor-
mation. Attack frequency is the
stronger predictor for migraine pro-
gression: prophylactic agents could
be administered to patients with a
high number of attacks. Medication
overuse is the most important iatro-
genic risk factor for the acceleration
of disease and it must be prevented;
other important risk factors are
female sex, obesity and stressful life
events.
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referred pain area (second order) and finally extracephalic
allodynia (third order). When central sensitisation occurs,
central trigeminal vascular neurons that receive conveying
sensory input from the meninges as well as from scalp and
facial skin can propagate information about pain process
without the need for further external stimuli. Manifestation of
cutaneous allodynia include discomfort when combing hair,
shaving and wearing glasses, contact lenses, earrings or tight
clothing. Sometimes muscle and extracephalic allodynia may
lead respectively to muscle tenderness and hypersensitivity of
fingertips and/or forearms and toes. Repeated episodes of
migraine with central sensitisation may contribute to disease
progression: correlation in fact was found between the dura-
tion of illness as well as frequency of migraine and allodynia.
It seems reasonable to infer from current knowledge that, in
the subset of patients who report symptoms of cutaneous allo-
dynia during migraine attacks, treatment designed to prevent
the initiation of central sensitisation can be the best interven-
tion to prevent the development of chronicity of migraine.
Early diagnosis of migraine could permit the application of a
treatment affecting the initiation of central sensitisation dur-
ing the attack. Thus a first migraine attack in a high-risk
patient may be viewed as a signal to begin protective therapy,
with the aim of altering the course of the disease.
Triptans can abort pain prior to the development of cen-
tral sensitisation, but not after allodynia has been established
[4]. Unfortunately, when central sensitisation and allodynia
are established, pharmacological agents only attenuate
migraine symptoms but do not stop the underlying patho-
physiologic process. Early initiation of triptan therapy is
currently the best intervention to achieve rapid, complete
and sustained pain relief and to prevent central sensitisation
during migraine attack. Therefore protective benefits against
migraine progression can derive from scrupulous manage-
ment of individual attacks with triptans.
The evolution from episodic to chronic headache may
reflect the neurologic disruption observed during the pro-
gression of an acute migraine attack and those changes in
neurologic function between episodes of headache may be
a sensitive indicator of headache transformation [5]. Early
recognition of nonheadache changes in nervous system
function may offer a sensitive and specific approach to
prevention of chronicity. From this perspective the evalu-
ation shifts from attack to a more global assessment of
neurological function of the patient with migraine.
Attack frequency
The strongest predictor for migraine progression is attack
frequency. Frequently recurring migraine episodes may pre-
dispose a person to disease chronicity through a permanent
status of central sensitisation. Neuroimaging studies showed
that brain white matter lesions increased with episode fre-
quency, possibly demonstrating progression of the disease
[6]. In addition, repetitive attacks may lead to chronic
headache through a progressive impairment of the central
antinociceptive system in the periaqueductal grey matter that
controls activity of the trigeminovascular system [7]. In this
context, prophylactic medication that acts to reduce the num-
ber of migraine attacks, more likely than abortive agents,
might have a long-term effect on the natural evolutive histo-
ry of migraine. Prophylactic agents could be administered
over a long enough period to truly affect disease progression.
Long duration prophylaxis (greater than 6 months) could be
recommended for patients with high attack frequency and
other risk factors for migraine progression. Drugs providing
a large decrease in attack frequency will have a correspond-
ing positive effect on disease progression.
Medication overuse
Medication overuse is commonly identified as the most
important iatrogenic risk factor for the acceleration of dis-
ease which leads to chronicity of migraine. Migraine patients
are particularly predisposed to develop chronic headache in
association with medication overuse [8]. The regular use of
symptomatic medications is associated with the development
of chronic headache in individuals who have an existing his-
tory of migraine; medication overuse per se did not cause the
development of headache de novo in patients without previ-
ous headache history. Analgesics and other antimigraine
drugs may be a cofactor in the development of chronicity in
a genetically vulnerable individual .The best strategy against
medication overuse includes several aspects but awareness
and prevention are the most important. This may be accom-
plished by setting limits to abortive medication overuse, in
particular anticipatory medication use should be discour-
aged, improving utilisation of prophylactic medication,
behavioural modification and nonpharmacological approach-
es to headache control earlier in the natural history of
migraine, without resorting to medication overuse.
Other risk factors for progression
Other risk factors for migraine progression are not read-
ily modifiable factors such as female sex, low educa-
tion/socioeconomic status, head injury and modifiable
factors such as obesity, stressful life events, snoring and
sleep disturbances [9].
Nonpharmacological intervention addressing the stress-
ful life events may also have an important protective action
on the development of chronicity of migraine. Cognitive-
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behavioural strategies aimed at reducing illness behaviour
such as biofeedback have demonstrated efficacy in reducing
the frequency and/or severity of migraine attacks.
Conclusions
The increasing recognition of migraine as a disorder
that is sometimes progressive creates opportunities for
intervention to prevent migraine progression. Emerging
treatment strategies to prevent disease progression
include risk factor modification, and possibly the use of
triptans as early as possible in the course of a migraine
episode and at the onset of the disease. A more aggres-
sive multidisciplinary approach to the treatment of
migraine is certainly warranted for many patients at
high risk of chronicity. The benefits of prospective
strategies to prevent migraine progression await testing
in well-designed studies.
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